Clinical Trials Logo

Clinical Trial Summary

This study is for slow growing tumors called plexiform neurofibromas (PNF) which are a relatively common problem in people with neurofibromatosis type 1 (NF1). These tumors are benign but as they grow, they can become disfiguring as well as disabling or even life threatening. They often cause pain, difficulty using arms or legs because of spinal cord compression, and/or nerve damage. At present, the only available therapy for plexiform neurofibromas is to try to surgically remove as much of the tumor as is possible. Because these tumors grow into the surrounding areas, total surgical resection is often impossible. Most tumors will re-grow after surgery if the entire tumor cannot be removed. To date, other treatments including chemotherapy and radiotherapy have not been able to shrink these tumors.

Interferon is a drug that is used for different types of tumors as well as for hepatitis. It has been used in the treatment of plexiform neurofibromas (PNF) with some subjects showing improvement in symptoms and/or a decrease in the size of the tumor. Most subjects had no further growth of their tumor while on the PEG-Intron. The drug used in this study is PEG (pegylated)-Intron. PEG-Intron is a long acting form of interferon which keeps the drug from being broken down in the body for a longer period of time and potentially could be more effective than the short-acting interferon. PEG-Intron has been approved by the Food and Drug Administration (FDA) for the treatment of Hepatitis C.

The goals of this study are:

1. To determine how your child's plexiform neurofibroma responds to PEG-Intron when given weekly.

2. To determine the side effects of PEG-Intron when given weekly to participants with plexiform neurofibromas.

3. To evaluate a new method of measuring changes in the size of tumors called volume analysis. This method measures the entire volume of a tumor in three dimensions. The standard method of measuring tumors uses only the length and/or width of the tumor. By studying the different ways of measuring tumors the investigators hope to be able to determine which method is the most accurate and useful.


Clinical Trial Description

PEG-Intron will be given every week through a small needle under the skin, in the same way that insulin is given to people with diabetes. Subjects will be taught to do this at home. As long as the tumor isn't growing and the side effects are tolerable, the injections will be given once a week for 2 years.

Children will be enrolled on the study into one of three strata (patient groups): strata 1 includes children who do not have any symptoms associated with their PNF and MRI scans over the past year may or may not show tumor growth, strata 2 includes children who have symptoms associated with the PNF but MRI scans over the past year have not shown growth and strata 3 includes children who have shown an increase in the size of the PNF on MRI scans over the past year, with or without any symptoms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00396019
Study type Interventional
Source University of Pittsburgh
Contact
Status Completed
Phase Phase 2
Start date December 2006
Completion date April 2014

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03962543 - MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Phase 2
Completed NCT03326388 - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Phase 1/Phase 2
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Active, not recruiting NCT03231306 - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Phase 2
Active, not recruiting NCT00326872 - AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine Phase 2
Active, not recruiting NCT04954001 - Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Phase 1/Phase 2
Recruiting NCT05913037 - FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Phase 3
Completed NCT00727233 - Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Phase 1
Active, not recruiting NCT03820778 - Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 N/A
Completed NCT01800032 - PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
Recruiting NCT06379230 - A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
Active, not recruiting NCT00924196 - Natural History Study of Patients With Neurofibromatosis Type I
Active, not recruiting NCT03363217 - Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. Phase 2
Not yet recruiting NCT06188741 - Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 Phase 2
Completed NCT01412892 - Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Phase 2